Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Cancer Metastatic × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 211 Carcinoma, Intraductal, Noninfiltrating 18 Breast Carcinoma In Situ 15 Neoplasm Metastasis 11 Breast Neoplasms, Male 11 Neoplasms 10 Ovarian Neoplasms 8 Inflammatory Breast Neoplasms 6 Glioblastoma 5 Endometrial Neoplasms 4 Central Nervous System Neoplasms 4 Prostatic Neoplasms 3 Gliosarcoma 3 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Breast Cancer Female 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Glioma 2 Fibroadenoma 2 ER+ Breast Cancer 2 Astrocytoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Sleep Wake Disorders 1 Sexuality 1 Sarcoma 1 Risk Reduction Behavior 1 Recurrence 1

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Gemcitabine 2 Capecitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡